Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IVHEHLMANN, Rüdiger; MÜLLER, Martin C; SCHNITTGER, Susanne et al.Journal of clinical oncology. 2014, Vol 32, Num 5, pp 415-423, issn 0732-183X, 9 p.Article

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 studyLILLY, Michael B; OTTMANN, Oliver G; BRADLEY-GARELIK, Mary Brigid et al.American journal of hematology. 2010, Vol 85, Num 3, pp 164-170, issn 0361-8609, 7 p.Article

Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic PhaseHUGHES, Timothy; SAGLIO, Giuseppe; KIM, Dongho et al.Journal of clinical oncology. 2009, Vol 27, Num 25, pp 4204-4210, issn 0732-183X, 7 p.Article

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-upKANTARJIAN, Hagop; CORTES, Jorge; BRIGID BRADLEY-GARELIK, M et al.Blood. 2009, Vol 113, Num 25, pp 6322-6329, issn 0006-4971, 8 p.Article

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemiasEMMANUEL NICOLINI, Franck; BASAK, Grzegorz W; SAGLIO, Giuseppe et al.Blood. 2011, Vol 118, Num 20, pp 5697-5700, issn 0006-4971, 4 p.Article

Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid LeukemiaBURCHERT, Andreas; MÜLLER, Martin C; KOSTREWA, Philippe et al.Journal of clinical oncology. 2010, Vol 28, Num 8, pp 1429-1435, issn 0732-183X, 7 p.Article

ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemiaERNST, Thomas; HOFFMANN, Jana; ERBEN, Philipp et al.Haematologica (Roma). 2008, Vol 93, Num 9, pp 1389-1393, issn 0390-6078, 5 p.Article

Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemiaBURCHERT, Andreas; WÖLFL, Stefan; GSCHAIDMEIER, Harald et al.Blood. 2003, Vol 101, Num 1, pp 259-264, issn 0006-4971, 6 p.Article

Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid LeukemiaHEHLMANN, Rüdiger; LAUSEKER, Michael; HÄNEL, Mathias et al.Journal of clinical oncology. 2011, Vol 29, Num 12, pp 1634-1642, issn 0732-183X, 9 p.Article

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IVSAUSSELE, Susanne; LAUSEKER, Michael; SCHLIMOK, Günter et al.Blood. 2010, Vol 115, Num 10, pp 1880-1885, issn 0006-4971, 6 p.Article

Exogenous reelin prevents granule cell dispersion in experimental epilepsyMÜLLER, Martin C; OSSWALD, Matthias; TINNES, Stefanie et al.Experimental neurology (Print). 2009, Vol 216, Num 2, pp 390-397, issn 0014-4886, 8 p.Article

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinibERNST, Thomas; ERBEN, Philipp; MÜLLER, Martin C et al.Haematologica (Roma). 2008, Vol 93, Num 2, pp 186-192, issn 0390-6078, 7 p.Article

An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCRMÜLLER, Martin C; SAGLIO, Giuseppe; STOCKINGER, Hubertus et al.Haematologica (Roma). 2007, Vol 92, Num 7, pp 970-973, issn 0390-6078, 4 p.Article

Dynamics of cytogenetic aberrations in philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failureFABARIUS, Alice; HAFERLACH, Claudia; MÜLLER, Martin C et al.Haematologica (Roma). 2007, Vol 92, Num 6, pp 834-837, issn 0390-6078, 4 p.Article

Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome―Positive Chronic Myeloid Leukemia in Chronic Phase Treated With NilotinibBRANFORD, Susan; KIM, Dong-Wook; HOCHHAUS, Andreas et al.Journal of clinical oncology. 2012, Vol 30, Num 35, pp 4323-4329, issn 0732-183X, 7 p.Article

Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapyHANFSTEIN, Benjamin; MÜLLER, Martin C; KREIL, Sebastian et al.Haematologica (Roma). 2011, Vol 96, Num 3, pp 360-366, issn 0390-6078, 7 p.Article

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVFABARIUS, Alice; LEITNER, Armin; JUNG-MUNKWITZ, Susanne et al.Blood. 2011, Vol 118, Num 26, pp 6760-6768, issn 0006-4971, 9 p.Article

BCR-ABL Mutations in Chronic Myeloid LeukemiaERNST, Thomas; LA ROSEE, Paul; MÜLLER, Martin C et al.Hematology/oncology clinics of North America. 2011, Vol 25, Num 5, issn 0889-8588, 997-1008, v-vi [14 p.]Article

Suitability of the PAXgene™ system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemiaERNST, Thomas; HOFFMANN, Jana; ERBEN, Philipp et al.Clinical chemistry and laboratory medicine. 2008, Vol 46, Num 3, pp 318-322, issn 1434-6621, 5 p.Article

Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instabilityFABARIUS, Alice; GIEHL, Michelle; SEIFARTH, Wolfgang et al.British journal of haematology. 2007, Vol 138, Num 3, pp 369-373, issn 0007-1048, 5 p.Article

ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisisSACHA, Tomasz; HOCHHAUS, Andreas; SKOTNICKI, Aleksander B et al.Leukemia research. 2003, Vol 27, Num 12, pp 1163-1166, issn 0145-2126, 4 p.Article

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNetSOVERINI, Simona; HOCHHAUS, Andreas; PORKKA, Kimmo et al.Blood. 2011, Vol 118, Num 5, pp 1208-1215, issn 0006-4971, 8 p.Article

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinibSHAH, Neil P; KIM, Dong-Wook; LAMBERT, Alexandre et al.Haematologica (Roma). 2010, Vol 95, Num 2, pp 232-240, issn 0390-6078, 9 p.Article

Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysisERBEN, Philipp; GOSENCA, Darko; HAFERLACH, Claudia et al.Haematologica (Roma). 2010, Vol 95, Num 5, pp 738-744, issn 0390-6078, 7 p.Article

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)HUGHES, Timothy P; HOCHHAUS, Andreas; RUDOLTZ, Marc S et al.Blood. 2010, Vol 116, Num 19, pp 3758-3765, issn 0006-4971, 8 p.Article